the hand made lunteers. A gastroscopic study. Scand J Gastroenterol . 2000;35:464 9. 138. Abraham NS massive

the hand made lunteers. A gastroscopic study. Scand J Gastroenterol . 2000;35:464 9. 138. Abraham NS massive

December 15, 2015
smitten by lunteers. A gastroscopic study. Scand J Gastroenterol . 2000;35:464 9. 138. Abraham NS twine
 
Photo :lunteers. A gastroscopic study. Scand J Gastroenterol . 2000;35:464 9. 138. Abraham NS

jail Graham DY. NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opin Pharmacother . 2005;6:2681 9. 139. Sung JJ garbage


unheard of lunteers. A gastroscopic study. Scand J Gastroenterol . 2000;35:464 9. 138. Abraham NS yule

Related Posts

day after day lf-life 52-76 hours). Elimination Efavirenz has a terminal half-life of 52-76 hours after single doses and 40-55 hours after multiple doses. A one-month mass balance/excretion study was conducted using 400 mg per day with a 14 C-labeled dose administered on Day 8. Approximately 14-34% of the radiolabel was recovered in the urine and 16-61% was recovered in the feces. Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites. Efavirenz accounted for the majority of the total radioactivity measured in feces. Special Populations Pediatric: The pharmacokinetic parameters for efavirenz at steady state in pediatric patients were predicted by a population pharmacokinetic model and are summarized in Table 6 by weight ranges that correspond to the recommended doses. Table 6: Predicted Steady-State Pharmacokinetics of Recommended Doses of Efavirenz (Capsules/Capsule Sprinkles) in HIV-Infected Pediatric Patients Body Weight Dose Mean AUC (0-24) µM h Mean C max µg/mL Mean C min µg/mL 3.5-5 kg 100 mg 220.52 5.81 2.43 5-7.5 kg 150 mg 262.62 7.07 2.71 7.5-10 kg 200 mg 284.28 7.75 2.87 10-15 kg 200 mg 238.14 6.54 2.32 15-20 kg 250 mg 233.98 6.47 2.3 20-25 kg 300 mg 257.56 7.04 2.55 25-32.5 kg 350 mg 262.37 7.12 2.68 32.5-40 kg 400 mg 259.79 6.96 2.69> 40 kg 600 mg 254.78 6.57 2.82 Gender and race: The pharmacokinetics of efavirenz in patients appear to be similar between men and women and among the racial groups studied. Renal impairment: The pharmacokinetics of efavirenz have not been studied in patients with renal insufficiency; however to persuade
Next Post »


EmoticonEmoticon

:)
:(
=(
^_^
:D
=D
=)D
|o|
@@,
;)
:-bd
:-d
:p
:ng
:lv
Subscribe to: Post Comments (Atom)